580 First-in-human, Safety, Pharmacokinetic (PK) and Pharmacodynamic (PD) Results From a Phase I Study of a Selective BRAF Inhibitor (BRAFi) RG7256 in Patients with BRAF V600-mutated Advanced Solid Tumors

Therapy response monitoring of the early effects of a new BRAF inhibitor on melanoma xenograft in mice: evaluation of 18F‐FDG‐PET and 18F‐FLT‐PET

“…A phase I clinical dose escalation study showed an improved safety profile for PLX3603 (11). No dose-limiting toxicities were observed, adverse events were mild to moderate and only 7% of the patients developed cuSCC (11). Efficacy of PLX3603 treatment was encouraging: 18 out of 44 patients showed stable disease, while 14 patients showed a partial response (11).…”

“…More importantly, PLX3603 had no effect on the tumor growth of A431 SCC xenografts, whereas vemurafenib treatment stimulated its growth (10). A phase I clinical dose escalation study showed an improved safety profile for PLX3603 (11). No dose-limiting toxicities were observed, adverse events were mild to moderate and only 7% of the patients developed cuSCC (11).…”